Vesalius Therapeutics
Cambridge, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $420M
Overview
A metabolic disease company creating small molecule drugs that target fundamental energy pathways.
MetabolicCardiovascular
Technology Platform
A discovery platform that uses metabolomics and computational systems biology to identify and validate novel drug targets in cellular energy pathways.
Funding History
4Total raised:$420M
Series D$105M
Series C$105M
Series B$105M
Series A$105M
Opportunities
Success in its lead program could redefine treatment for heart failure with preserved ejection fraction (HFpEF), a massive unmet need.
Risk Factors
Pioneering novel metabolic targets carries a high risk of unforeseen biological complexity and clinical failure.
Competitive Landscape
Competes with other biotechs and pharma giants pursuing novel mechanisms in cardiometabolic disease, a high-stakes area with recent clinical failures.